恒信東方(300081.SZ):《Drakheir》目前已登錄Quest第三方應用平台Sidequest公測
格隆匯6月7日丨恒信東方(300081.SZ)接受機構調研、現場參觀,交流環節中,就“請介紹公司手勢交互遊戲《Drakheir》”
公司回覆稱,《Drakheir》(暫定名)是公司自研的一款魔法戰鬥Roguelite遊戲,基於Meta Quest 2平台的“裸手”手勢互動技術,目前已登錄Quest第三方應用平台Sidequest公測。該產品基於歐美魔幻風美術風格,應用PBR物理渲染+NPR風格化混合美術管線,在手勢追蹤、實時光影的渲染表現、物理模擬、功能架構創新、算法優化、行為預測等多個領域進行了深度的技術攻克及突破。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.